A persistent question in the management of infected diabetic foot ulcers (DFUs) is deceptively simple: Does it matter whether we swab or take tissue? Guidelines emphasize tissue sampling, yet swabbing is easier, cheaper, and far more widely used. The CODIFI2 randomized controlled trial, published in Health Technology Assessment (2025), offers timely insight — though, as the authors acknowledge, not definitive answers.
This UK-led trial (21 clinics; planned sample size 730) was halted early due to poor recruitment and pandemic-related constraints, enrolling only 149 patients with suspected mild or moderate infected DFUs. Despite being underpowered, CODIFI2 adds useful context at the intersection of practice, microbiology, cost, and patient-centered outcomes.
What the Trial Asked
CODIFI2 set out to determine whether tissue samples versus swabs impact:
- Time to ulcer healing (primary outcome)
- Rates of healing
- Antibiotic prescribing patterns
- Cost of care
- Safety, adverse events, and quality of life
Importantly, the trial also included several nested substudies to assess agreement between molecular vs standard culture, clinician decision-making, health economics, and survey methodology.
What CODIFI2 Found
1. Healing outcomes were essentially identical
- Hazard ratio for healing: 1.01 (95% CI, 0.65–1.55)
- No meaningful difference in time to healing or proportion healed
- Slightly more adverse events and amputations in the tissue group (with wide uncertainty)
2. Swabs were less expensive and associated with higher quality-adjusted life-years
Across most timepoints, QALYs favored swabs, and overall cost of care was lower.
3. Molecular microbiology detected more organisms — but didn’t clarify management
Substudy 1 showed low agreement between standard culture and molecular techniques.
Providers were 20.5% more likely to recommend changing antibiotics when shown the molecular report.
Yet clinicians expressed discomfort interpreting molecular results, citing unfamiliar reporting formats.
4. Tissue sampling led to more antibiotic use
Even though tissue detects more organisms, this did not translate into better outcomes — and may have contributed to broader-spectrum or longer-duration therapy.
5. Modeling suggested molecular analysis costs ~£120 more per wound
With no clear improvement in clinical outcomes or patient experience.
What This Means for Practice
Although underpowered, CODIFI2 raises important considerations:
- For mild-to-moderate DFU infection, swabbing appears acceptable, cost-effective, and less burdensome — at least until higher-quality evidence emerges.
- Tissue sampling remains guideline-supported, especially when deeper infection or osteomyelitis is suspected.
- More organisms ≠ better decisions. Molecular techniques improve detection but may complicate antibiotic selection without definitive clinical benefit.
- Antimicrobial stewardship matters. Tissue sampling increased antibiotic exposure without improving outcomes.
This echoes a broader reality in limb preservation: technology that increases data volume does not automatically increase clinical value. The challenge — and opportunity — is designing systems that provide actionable insights without intensifying complexity or cost.
Full Citation
Nelson EA, Everett CC, Konwea H, et al. “Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT.” Health Technol Assess. 2025;29(59):1–53. doi:10.3310/KKPP0404. PMID: 41217802.
Leave a Reply